ImmuCell Corp (ICCC) FinancialsICCCFinancialImmuCell Corp

ImmuCell Corp (ICCC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is First Defense® product line, accounting for 99.5% of total sales, equivalent to $10.31M. Another important revenue stream is Other animal health. Understanding this composition is critical for investors evaluating how ICCC navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, ImmuCell Corp maintains a gross margin of 33.92%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 26.93%, while the net margin is 25.53%. These profitability ratios, combined with a Return on Equity (ROE) of 2.57%, provide a clear picture of how effectively ICCC converts its operational activities into shareholder value.

In the context of the broader market, ICCC competes directly with industry leaders such as ALDX and RLYB. With a market capitalization of $91.28M, it holds a significant position in the sector. When comparing efficiency, ICCC's gross margin of 33.92% stands against ALDX's N/A and RLYB's 100.00%. Such benchmarking helps identify whether ImmuCell Corp is trading at a premium or discount relative to its financial performance.

ImmuCell's revenue for Q2 2026 was $7.2 million, an 11.5% increase year-over-year, but the gross margin fell to 33.92%. Net income for Q2 was $1,831,656, showing improvement from previous quarters.